In a welcome move, DexCom stock saw its Relative Strength Rating improve from 68 to 73 on Monday.
This unique rating measures technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 in the early stages of their moves. See if DexCom stock can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Is DexCom Stock A Buy?
DexCom stock is still within a buying range after breaking past a 132.03 entry in a flat base. Once a stock moves 5% or higher beyond the initial entry, it's considered extended and out of buy range.
The medical device company showed 47% EPS growth in the latest quarterly report. Sales gains came in at 27%.
DexCom stock earns the No. 3 rank among its peers in the Medical-Products industry group. LifeMD is the top-ranked stock within the group.
